Cynvec
Pioneering innovative cancer treatment through groundbreaking viral vector research.
Pioneering innovative cancer treatment through groundbreaking viral vector research.
Cynvec is an innovative biotech firm founded in 2004 in New York City, focusing on pioneering research by Dr. Daniel Meruelo, Ph.D., a leading expert on the sindbis oncolytic viral vector for cancer treatment, based on exclusive licensing of intellectual property from New York University. The company is currently preparing an investigational new drug application (IND) for its first product, CYN 101. The latest $1.90M Venture Round investment in December 07, 2015 reflects confidence in Cynvec's groundbreaking viral vector research to pioneer innovative cancer treatment. With its focus on biotechnology and health care, Cynvec holds significant potential for long-term impact and growth in the biotech sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $1.90M | - | 07 Dec 2015 | |
| Venture Round | $500.00K | - | 20 Mar 2009 |
No recent news or press coverage available for Cynvec.
We care about your data, and we'd love to use cookies make your experience better.
